OAM
IMCR icon

Oppenheimer Asset Management’s Immunocore IMCR Stock Holding History

Oppenheimer Asset Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,582
Closed -$228K – 1139
2025
Q4 		$228K Sell
6,582
-352
-5% -$12.4K ﹤0.01% 973
2025
Q3 		$252K Sell
6,934
-101
-1% -$3.43K ﹤0.01% 1043
2025
Q2 		$221K Sell
7,035
-539
-7% -$16.7K ﹤0.01% 1066
2025
Q1 		$225K Buy
+7,574
New +$227K ﹤0.01% 1026
2024
Q4 		– Sell
-8,045
Closed -$250K – 1174
2024
Q3 		$250K Sell
8,045
-118
-1% -$4.29K ﹤0.01% 1040
2024
Q2 		$277K Buy
8,163
+43
+0.5% +$2.19K ﹤0.01% 996
2024
Q1 		$528K Sell
8,120
-131
-2% -$8.99K 0.01% 820
2023
Q4 		$564K Buy
8,251
+760
+10% +$39.5K 0.01% 841
2023
Q3 		$389K Buy
7,491
+1,572
+27% +$93K 0.01% 905
2023
Q2 		$355K Buy
+5,919
New +$338K 0.01% 938

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Oppenheimer Asset Management's IMCR Position: Q1 2026 in Review

Oppenheimer Asset Management sold out of Immunocore (IMCR) in Q1 2026, closing a stake of 6,582 shares — an estimated $228K sold.

Oppenheimer Asset Management first reported a position in IMCR in Q2 2023 and held it in 10 quarters. The position peaked at $564K in Q4 2023. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

  • Oppenheimer Asset Management reported no remaining Immunocore position as of Q1 2026 after selling out during the quarter.
  • Oppenheimer Asset Management sold 6,582 Immunocore shares in Q1 2026, an estimated $228K.
  • Oppenheimer Asset Management first reported a position in Immunocore in Q2 2023 and held it in 10 quarters.
  • Oppenheimer Asset Management's Immunocore position peaked at $564K in Q4 2023.
  • 142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.